Entities / Company
National Comprehensive Cancer Network.
non-profit organization in the USA
- Reports this week
- 0
- Active events
- 0
- Connections
- 33
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
-
The American Cancer Society and National Comprehensive Cancer Network published findings in a journal regarding cancer in the United States.Well supported7 reports
-
Updated guidelines from the National Comprehensive Cancer Network are driving the adoption and frequency of clonoSEQ testing, with Medicare coverage providing a foundation for reimbursement.Some support2 reports
-
NCCN reported on the current status of drug shortages across the United States.Some support4 reports
-
The FDA approved a drug for advanced breast cancer patients, and the recommended regimens were designated as preferred Category 1 options by the National Comprehensive Cancer Network.Some support3 reports
-
Guardant Health reported results from Palo Alto on July 31, 2025. Shield MCD received Breakthrough Device Designation from the FDA and was included in NCCN colorectal cancer screening guidelines.Well supported4 reports3 developments inside
-
PEDMARK therapy received recognition from the National Comprehensive Cancer Network (NCCN) on August 11, alongside Fennec evaluating partnerships in Japan.Some support1 report
-
The European Institute of Oncology and the National Comprehensive Cancer Network are involved in a recent development.Some support1 report
Gone quiet
No new reports in 90+ days-
Guidelines reflect growing alignment among key organizations, involving the National Comprehensive Cancer Network and Infectious Diseases Society of America.Some support1 report
-
ImmunityBio initiated Phase 1 trials for NSCLC in US sites, while the FDA remained supportive of new data and the company sought guideline expansion from NCCN.Some support1 report
-
Taletrectinib was added to NCCN guidelines and selected as a preferred agent for cancer treatment.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around National Comprehensive Cancer Network this week
News at the entities that move National Comprehensive Cancer Network most-
FDA StructuralFDA conducted surprise raids and inspections in Bihar state, directed by state government officials.Moves National Comprehensive Cancer Network
-
Guardant Health StructuralBrightSpring Health Services and Guardant Health have both been listed on the Nasdaq stock exchange.Moves National Comprehensive Cancer Network
-
Philippines OperationalA new facility/project has been established in Quezon City to serve the Metro Manila market.Moves National Comprehensive Cancer Network
-
Gilead Sciences OperationalAmgen and Gilead Sciences are two companies that compete within the biotech industry.Moves National Comprehensive Cancer Network
-
American Cancer Society Mentioned togetherKai Trump posted a video with his mother, Vanessa Trump, while the American Cancer Society provided data on breast cancer rates.Moves National Comprehensive Cancer Network
-
Manila Shared contextRDC's operations in Manila are characterized by embedded circular practices.Moves National Comprehensive Cancer Network
Connections
The 10 strongest of 33, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Philippines Operational
NCCN actively collaborates with the Philippines to adapt and publish cancer treatment guidelines.
-
FDA Structural
FDA approvals serve as the necessary regulatory basis upon which the National Comprehensive Cancer Network builds its clinical treatment guidelines.
-
Guardant Health Structural
NCCN formally included Guardant Health's Shield test in its colorectal cancer screening guidelines.
-
Gilead Sciences Operational
NCC review directly influences the preferred status of Gilead's drugs.
-
American Cancer Society Mentioned together
Both entities were mentioned in a journal publication regarding cancer findings.
-
European Institute of Oncology Structural
The European Institute of Oncology is formally affiliated with the National Comprehensive Cancer Network.
-
ImmunityBio Operational
ImmunityBio actively engages the National Comprehensive Cancer Network to seek guideline expansion and operates within its clinical context.
-
Evans Structural
NCCN formally recognized Evans' PEDMARK therapy, indicating structural validation of the company's product.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
2 eventsAugust 2026
4 events- The American Cancer Society and National Comprehensive Cancer Network published findings in a journal regarding cancer in the United States.
- The FDA approved a drug for advanced breast cancer patients, and the recommended regimens were designated as preferred Category 1 options by the National Comprehensive Cancer Network.
- PEDMARK therapy received recognition from the National Comprehensive Cancer Network (NCCN) on August 11, alongside Fennec evaluating partnerships in Japan.
- The European Institute of Oncology and the National Comprehensive Cancer Network are involved in a recent development.
Show 1 earlier month
June 2026
4 events- Guardant Health reported results from Palo Alto on July 31, 2025. Shield MCD received Breakthrough Device Designation from the FDA and was included in NCCN colorectal cancer screening guidelines.
- Guidelines reflect growing alignment among key organizations, involving the National Comprehensive Cancer Network and Infectious Diseases Society of America.
- ImmunityBio initiated Phase 1 trials for NSCLC in US sites, while the FDA remained supportive of new data and the company sought guideline expansion from NCCN.
- Taletrectinib was added to NCCN guidelines and selected as a preferred agent for cancer treatment.